Cytek Biosciences (CTKB) Operating Leases (2022 - 2026)

Cytek Biosciences has reported Operating Leases for 5 years, with the latest figure at $13.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 80.46% year-over-year to $13.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.4 million (up 80.46% YoY), and the FY2025 full-year result was $14.0 million, up 24.18% from the prior year.
• Operating Leases for Q1 2026 stood at $13.4 million, down from $14.0 million in the prior quarter.
• The five-year high for Operating Leases was $17.4 million in Q2 2025, with the low at $7.4 million in Q1 2025.
• Historically, Operating Leases has averaged $12.1 million across 5 years, with a median of $11.5 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Leases sank 37.81% — and 2026, when it soared 80.46%.
• Cytek Biosciences' Operating Leases stood at $15.2 million in 2022, then slumped by 37.81% to $9.5 million in 2023, then increased by 19.3% to $11.3 million in 2024, then climbed by 24.18% to $14.0 million in 2025, then retreated by 4.28% to $13.4 million in 2026.
• The last three Operating Leases figures came in at $13.4 million (Q1 2026), $14.0 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.